The present invention provides a method for producing a platelet comprising: (a) a step of culturing a megakaryocyte for at least 6 days in a platelet production medium in which a turbulent flow is generated; and (b) a step of injecting the medium comprising the megakaryocyte that has undergone step (a) into a predetermined platelet production device to expose the megakaryocyte to a laminar flow.

The present invention relates on a process for preparing platelet lysate fraction, said process comprising the steps of: 1) providing a platelet lysate, 2) collecting from said platelet lysate a fraction wherein the components exhibit a maximum molecular weight of 100 kDa, on a specific platelet lysate fraction and its use as a drug.

Provided herein are methods for the isolation of platelets, for example, isolation of platelets from umbilical cord blood. In certain embodiments, presented herein are methods for preparation of platelet rich plasma. In one aspect, provided herein are methods for isolation of platelets from blood. In certain embodiments, presented herein are methods for isolation of platelets from cord blood, e.g., human cord blood. The isolated platelets can be used for a variety of applications, including, for example, methods of wound healing, organ repair and/or regeneration, and/or tissue repair and/or regeneration, in either autologous or allogenic settings.

A blood isolation and extraction method includes: providing a predetermined amount of blood; utilizing a platelet filter unit to filter the predetermined amount of blood to generate a filtered blood; utilizing a plasma separation unit to divide the filtered blood into a plasma layer and a blood cell layer for separating blood cells from blood plasma; and extracting the blood plasma from the plasma layer and the blood cells from the blood cell layer. In another embodiment, the blood isolation and extraction method further includes: providing a platelet-washing unit to wash the platelet filter unit with a solution to produce a platelet solution; and mixing the platelet solution with the blood plasma to produce a platelet and plasma mixed solution.

Disclosed herein are compositions and methods related to megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells, where the megakaryocyte-derived extracellular vesicles may be utilized for drug delivery and treating various diseases.

A method for washing platelets includes introducing anticoagulant into a platelet product container, drawing re-anticoagulated platelet product from the platelet product container, and introducing it into a centrifuge bowl. The centrifuge bowl separates the platelets from the supernatant in which they are suspended. The method then washes the platelets by introducing wash solution into the centrifuge bowl. As the wash solution is introduced into the bowl, it displaces the supernatant from the bowl and into a waste container. The method then introduces platelet additive solution into the centrifuge bowl, which displaces the wash solution from the centrifuge bowl and into the waste container and further wash the platelets. The method then repeatedly accelerates and decelerates the centrifuge bowl to resuspend the platelets in the platelet additive solution.

The present disclosure provides methods for generating megakaryocytes and novel platelet variants from the same CD34+ progenitor stem cells, which comprises at least two stages: stage zero (0) comprising an expansion and maintenance stage of the CD34+ progenitor stem cells for a period ranging between 0 hours to 48 hours; and, stage one (I) comprising a differentiation phase wherein the differentiation phase comprises differentiating the CD34+ progenitor stem cells in step (i) for a period sufficient to generate substantially matured megakaryocytes. Novel platelet variants are produced by passaging the megakaryocytes, produced by the CD34+ progenitor stem cells, through a bioreactor or a fluidic device. Formulations comprising megakaryocytes and platelet variants derived from CD34+ progenitor stem cells and methods of their use are also disclosed.

Antibodies and antigen-binding antibody fragments that bind to GPIIb/IIIa and chimeric polypeptides comprising these binding molecules are disclosed. Some of these antibodies and antigen-binding antibody fragments preferentially bind GPIIb/IIIa on activated platelets while others do not show a preference for binding GPIIb/IIIa on resting versus activated platelets. Some of these antibodies and antibody fragments do not inhibit the interaction of GPIIb/IIIa with fibrinogen, while some others do. The disclosed antibodies do not induce platelet activation. Some of these antibodies and antigen-binding antibody fragments are useful in targeting therapeutic agents such as clotting factors to platelets while others are useful in reducing platelet aggregation and/or thrombus formation.

The present invention is directed to indirect ultrasonic cavitation-derived perivascular cells, to methods of use of a perivascular cell composition, to a method of processing a tissue and to an apparatus for the processing of a tissue. The methods include the mechanic indirect ultrasonication of a cellular non-structural tissue, and produce a perivascular fraction which includes perivascular cells. The methods of use are directed to the treatment of a variety of diseases and disorders and to the improvement of a tissue in a subject. The apparatus is provided for the processing of cellular non-structural tissue.

A system and a method are disclosed for obtaining a plasma composition enriched with bioactive molecules such as growth factors and cytokines and depleted in contaminants such as viruses.